You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors

Article metrics

Article menu

Download PDFPDF

Late-breaking abstracts
Clinical trials completed
794 Safety and efficacy results from a phase 1/1b study of intratumoral MK-4621, a retinoic acid-inducible gene I (RIG-I) agonist, plus intravenous pembrolizumab in patients with advanced solid tumors

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020217021
Dec 20203208
Jan 202164012
Feb 20216608
Mar 202198028
Apr 20213805
May 202142014
Jun 20210018
Jul 20210019
Aug 20210012
Sep 20210014
Oct 2021106031
Nov 202174025
Dec 202194015
Jan 202254028
Feb 202288031
Mar 2022164021
Apr 2022102017
May 202270012
Jun 202266011
Jul 20224808
Aug 20224003
Sep 20224209
Oct 20225506
Nov 2022114016
Dec 20227609
Jan 20235407
Feb 202374012
Mar 202372010
Apr 202346015
May 202352010
Jun 20238606
Jul 20231605
Aug 20232804
Sep 20237409
Oct 20233406
Nov 20237007
Dec 20234606
Jan 20243603
Feb 202430013
Mar 202470016
Apr 202450020
May 20245005
Jun 20244802
Jul 20247606
Aug 20242201
Sep 20243408
Oct 20247005
Nov 202434010
Dec 20244807
Jan 202544012
Feb 20251403
Mar 20250013
Apr 20250010
May 2025004
Jun 2025006
Total30280642